PACIRA BIOSCIENCES, INC. Restructuring and Related Cost, Number of Positions Eliminated
PACIRA BIOSCIENCES, INC. (PCRX) reported Restructuring and Related Cost, Number of Positions Eliminated of 71 employee for the 1-month period ending 2025-07-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2026-02-26
- 2025-07-31: Restructuring and Related Cost, Number of Positions Eliminated 1 month 71.00 employee.
- 2025-07-09: Restructuring and Related Cost, Number of Positions Eliminated 71.00 employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated | Restructuring and Related Cost, Number of Positions Eliminated 1 month |
|---|---|---|
| 2025-07-31 | 71.00 employee 10-K · filed 2026-02-26 | |
| 2025-07-09 | 71.00 employee 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |